SCHEMBL6095920

SCHEMBL6095920

CS(=O)(=O)OCCCN(C(=O)OCc1ccccc1)c1cccc[n+]1[O-]

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR6 P51684 1/20 0.35
PAX8 Q06710 1/20 0.35
ALDH1A1 P00352 6/20 0.35
F13A1 P00488 1/20 0.34
TGM2 P21980 1/20 0.34
TGM1 P22735 1/20 0.34
MAPT P10636 2/20 0.34
HPGD P15428 1/20 0.34
LMNA P02545 2/20 0.33
MAPK1 P28482 2/20 0.33
L3MBTL1 Q9Y468 2/20 0.33
CYP3A4 P08684 1/20 0.33
TSHR P16473 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
PTGDR2 Q9Y5Y4 1/20 0.33
SIGMAR1 Q99720 1/20 0.33
CA1 P00915 3/20 0.32
CA2 P00918 3/20 0.32
CA12 O43570 2/20 0.32
CA9 Q16790 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6094085 0.83 CCR6 (0.43) CCR6PAX8ALDH1A1MAPTHPGD
SCHEMBL6180961 0.83 L3MBTL1 (0.34) L3MBTL1CA1CA12
SCHEMBL6859257 0.82 HTT (0.43) CCR6PAX8ALDH1A1MAPTHPGD
SCHEMBL6177046 0.80 L3MBTL1 (0.32) L3MBTL1
SCHEMBL6853751 0.80 HTT (0.42) CCR6PAX8ALDH1A1MAPTHPGD
SCHEMBL1042317 0.77 F13A1 (0.47) CCR6PAX8ALDH1A1F13A1TGM2
SCHEMBL6112077 0.76 F13A1 (0.36) CCR6PAX8ALDH1A1F13A1TGM2
SCHEMBL13661578 0.75 CCR6 (0.49) CCR6PAX8ALDH1A1LMNAMAPK1
SCHEMBL18041390 0.74 CCR6 (0.51) CCR6PAX8ALDH1A1LMNAMAPK1
SCHEMBL15055271 0.73 CCR6 (0.51) CCR6PAX8ALDH1A1F13A1TGM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7101876-B2 Substituted benzoxazines as integrin antagonists PHARMACIA CORPORATION (US) 2006-09-05 US disclosed
US-20040224948-A1 Novel substituted benzoxazines as integrin antagonists PHARMACIA & UPJOHN S.P.A. (IT) 2004-11-11 US disclosed
US-6750215-B2 ANTITUMOR AGENTS; ANTICANCER AGENTS PHARMACIA & UPJOHN, S.P.A. (IT) 2004-06-15 US disclosed
US-20030073688-A1 Novel substituted benzoxazines as integrin antagonists POLSTER, RACHEL A. 2003-04-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040224948-A1 Novel substituted benzoxazines as integrin antagonists ITGB1, ITGA1, ITGB3 CCR6 2053/4885PAX8 4319/4885ALDH1A1 620/4885
US-20030073688-A1 Novel substituted benzoxazines as integrin antagonists ITGB1, ITGA1, ITGB3 CCR6 2053/4885PAX8 4319/4885ALDH1A1 620/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.